BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 34246076)

  • 1. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
    Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
    Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
    Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
    Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
    Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
    Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel combination of imipridones and histone deacetylase inhibitors demonstrate cytotoxic effect through integrated stress response in pediatric solid tumors.
    Chang WI; Honeyman JN; Zhang J; Lin C; Sharma A; Zhou L; Oliveira J; Tapinos N; Lulla RR; Prabhu VV; El-Deiry WS
    Am J Cancer Res; 2023; 13(12):6241-6255. PubMed ID: 38187038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer
    Ray JE; Ralff MD; Jhaveri A; Zhou L; Dicker DT; Ross EA; El-Deiry WS
    Cancer Biol Ther; 2021 Dec; 22(10-12):554-563. PubMed ID: 34696710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.
    Talekar MK; Allen JE; Dicker DT; El-Deiry WS
    Cell Cycle; 2015 Aug; 14(15):2422-8. PubMed ID: 26030065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo.
    Jhaveri AV; Zhou L; Ralff MD; Lee YS; Navaraj A; Carneiro BA; Safran H; Prabhu VV; Ross EA; Lee S; El-Deiry WS
    Cancer Biol Ther; 2021 Dec; 22(10-12):607-618. PubMed ID: 34856854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
    Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Dopamine Receptors in the Anticancer Activity of ONC201.
    Kline CLB; Ralff MD; Lulla AR; Wagner JM; Abbosh PH; Dicker DT; Allen JE; El-Deiry WS
    Neoplasia; 2018 Jan; 20(1):80-91. PubMed ID: 29216597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
    Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
    Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF
    Fu H; Cheng L; Sa R; Jin Y; Chen L
    J Cell Mol Med; 2020 Mar; 24(6):3336-3345. PubMed ID: 31970877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ONC201/TIC10 plus TLY012 anti-cancer effects via apoptosis inhibitor downregulation, stimulation of integrated stress response and death receptor DR5 in gastric adenocarcinoma.
    Parker CS; Zhou L; Prabhu VV; Lee S; Miner TJ; Ross EA; El-Deiry WS
    Am J Cancer Res; 2023; 13(12):6290-6312. PubMed ID: 38187068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
    Allen JE; Krigsfeld G; Patel L; Mayes PA; Dicker DT; Wu GS; El-Deiry WS
    Mol Cancer; 2015 May; 14():99. PubMed ID: 25927855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist.
    Frew AJ; Lindemann RK; Martin BP; Clarke CJ; Sharkey J; Anthony DA; Banks KM; Haynes NM; Gangatirkar P; Stanley K; Bolden JE; Takeda K; Yagita H; Secrist JP; Smyth MJ; Johnstone RW
    Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11317-22. PubMed ID: 18685088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine pre-treatment impairs the anti-cancer effect of integrated stress response- and TRAIL pathway-inducing ONC201, ONC206 and ONC212 imipridones in pancreatic, colorectal cancer but not DMG cells.
    Zhang Y; Tapinos N; Lulla R; El-Deiry WS
    Am J Cancer Res; 2024; 14(5):2453-2464. PubMed ID: 38859853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
    Xin DE; Liao Y; Rao R; Ogurek S; Sengupta S; Xin M; Bayat AE; Seibel WL; Graham RT; Koschmann C; Lu QR
    Neuro Oncol; 2024 Apr; 26(4):735-748. PubMed ID: 38011799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.
    Knutson SK; Kawano S; Minoshima Y; Warholic NM; Huang KC; Xiao Y; Kadowaki T; Uesugi M; Kuznetsov G; Kumar N; Wigle TJ; Klaus CR; Allain CJ; Raimondi A; Waters NJ; Smith JJ; Porter-Scott M; Chesworth R; Moyer MP; Copeland RA; Richon VM; Uenaka T; Pollock RM; Kuntz KW; Yokoi A; Keilhack H
    Mol Cancer Ther; 2014 Apr; 13(4):842-54. PubMed ID: 24563539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
    Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
    Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy.
    Wang J; Wang H; Wang LY; Cai D; Duan Z; Zhang Y; Chen P; Zou JX; Xu J; Chen X; Kung HJ; Chen HW
    Cell Death Differ; 2016 Nov; 23(11):1886-1896. PubMed ID: 27612013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
    Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
    Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.